Search in the HOVON website
1. Autonomy of HOVON
It is of much interest to HOVON to maintain its autonomy in respect of the other stakeholders in the field. The HOVON believes firmly that this autonomy is a vital principle to make it possible for trials to be carried out independently and objectively, and in that way actually make a contribution to the further enrichment and broadening of medical knowledge.
The HOVON therefore operates independently of the various industrial parties, government and the KWF. The HOVON does however collaborate closely with each of these parties.
2. Collaboration within trials
In the field of patient-based research, the HOVON and the pharmaceutical industry collaborate closely. Wherever HOVON requires financial support for its trials, the pharmaceutical industry is often in search of new scientifically-confirmed insights into its medicines.
For each trial where such collaboration takes place, a trial agreement is drawn up. In this agreement, with the HOVON as sponsor, the various responsibilities and authorities are laid down. Also laid down are the cost items to be covered by the industry, arising from the trial. This includes possibly the medication to be provided, the costs of submission, the costs of data management and the additional diagnostic determinations.
The vast majority of these payments are passed on to the participating centres. A small portion is reserved to cover the overhead costs of the HOVON organisation.
Once the contracts have been entered into, the industry interacts directly with the trial manager at the HOVON Data Center (HDC), with a view to organising the logistics for the trial medication and entire safety organisation.
If the trial is open, the industry partner, via a so-called TOP logon, can at any time consult the trial database, to see which centres are participating and how inclusion is progressing.
It goes without saying that in the interim, the industrial partner is given access to the results of any interim analyses carried out, and final analysis is also presented to the industry partner.
3. Unrestricted grants
As well as payment for specific trials, various industrial parties also issue unrestricted grants to the HOVON. The HOVON uses this funding to further professionalise its foundation and to strengthen haematological care in the various regions.
Spearheads of current policy at HOVON are:
- Echelon programming, whereby centres can be classified in a particular echelon: this determines the trials in which they can and cannot participate;
- Regionalisation, the objective of which is to increase participation of centres in the peripheral areas, for example by deploying trial consultants, and intensifying the system of consultations from the academic centre;
International collaboration, so that inclusion can be accelerated, and economies of scale achieved.
If you are interested in (closer) collaboration with the HOVON, please contact the HOVON Central Office